Food Waste Causes in Fruit and Vegetables Supply Chains

Fruit and vegetables are a core component of healthy diets, but horticultural production and distribution activities suffer from a high incidence of surplus food and food waste. The intrinsic perishability of products as well recurring pests, diseases and contamination events are since long recognized to be primary reasons for fruit and vegetables wastage, but a more thorough knowledge of causes, including external events and internal strategies and practices, is necessary to design and implement waste reduction strategies. However, literature on waste causes in fruit and vegetables supply chains is rather fragmented. Most existing studies focus on single products, single deterioration mechanisms or single reuse or recycling choices, and hardly ever investigate more than one stage of the fruit and vegetables supply chain. The main objective of the paper is to offer an instrument for identifying in a comprehensive way the possible origin points and root issues behind food waste generation in the stages of fruit and vegetables supply chains. The research is conducted through the application of two methods. A first phase consists in a deep literature review, whose results are summarized in the so-called Causes Framework. This qualitative instrument shows the possible sources of fruit and vegetables surplus and waste, highlighting for each supply chain stage the high-priority causes and for each cause the fundamental root issue. The second research phase is a case study that shows how the Framework can be applied to pinpoint the most significant causes for specific supply chains. The unit of analysis is the supply chain of an Italian PGI pear. Primary information is gathered from 6 enterprises through 7 semi-structured interviews. The most critical causes of surplus and waste generation in the focal supply chain are found as the intersection between interview answers and Framework predictions. The paper integrates sparse pieces of knowledge on the processes of food waste generation in fruit and vegetables supply chains, and offers an instrument that may support private and public decision-makers in the reduction of horticultural waste

Induction of Lymphocyte Apoptosis by Tumor Cell Secretion of FasL-bearing Microvesicles

The hypothesis that FasL expression by tumor cells may impair the in vivo efficacy of antitumor immune responses, through a mechanism known as ‘Fas tumor counterattack,’ has been recently questioned, becoming the object of an intense debate based on conflicting results. Here we definitely show that FasL is indeed detectable in the cytoplasm of melanoma cells and its expression is confined to multivesicular bodies that contain melanosomes. In these structures FasL colocalizes with both melanosomal (i.e., gp100) and lysosomal (i.e., CD63) antigens. Isolated melanosomes express FasL, as detected by Western blot and cytofluorimetry, and they can exert Fas-mediated apoptosis in Jurkat cells. We additionally show that melanosome-containing multivesicular bodies degranulate extracellularly and release FasL-bearing microvesicles, that coexpress both gp100 and CD63 and retain their functional activity in triggering Fas-dependent apoptosis of lymphoid cells. Hence our data provide evidence for a novel mechanism potentially operating in Fas tumor counterattack through the secretion of subcellular particles expressing functional FasL. Such vesicles may form a sort of front line hindering lymphocytes and other immunocompetent cells from entering neoplastic lesions and exert their antitumor activity

Synthesis of N-oxyamide analogues of protein kinase B (Akt) targeting anionic glycoglycerolipids and their antiproliferative activity on human ovarian carcinoma cells

Funding Information: The authors would like to acknowledge Industriale Chimica srl for funding the fellowship to M. Z. and M. Q. in memoriam of the founder Dr Fulvio Benigni as well as Associazione Italiana per la Ricerca sul Cancro (grant number 24725). The authors also thank Prof. Fiamma Ronchetti and Dr Paola Rota for the helpful discussion. Publisher Copyright: © 2023 The Royal Society of Chemistry.N-Oxyamides of bioactive anionic glycoglycerolipids based on 2-O-β-d-glucosylglycerol were efficiently prepared. However, the oxidation step of the primary hydroxyl group of the glucose moiety in the presence of the N-oxyamide function appeared to be a difficult task that was nevertheless conveniently achieved for the first time by employing a chemoenzymatic laccase/TEMPO procedure. The obtained N-oxyamides exhibited a higher inhibition of proliferation of ovarian carcinoma IGROV-1 cells in serum-free medium than in complete medium, similarly to the corresponding bioactive esters. Stability and serum binding studies indicated that the observed reduced activity of the compounds in complete medium could be mainly due to a binding effect of serum proteins rather than the hydrolytic degradation of glycoglycerolipid acyl chains. Furthermore, the results of the cellular studies under serum-free conditions suggested that the N-oxyamide group could increase the antiproliferative activity of a glycoglycerolipid independently of the presence of the anionic carboxylic group. Cellular studies in other cell lines besides IGROV-1 also support a certain degree of selectivity of this series of compounds for tumor cells with Akt hyperactivation.publishersversionpublishe

Reducing food waste in food manufacturing companies

Putting unsold food at good use is clearly a high-priority option according to the Food Waste Hierarchy, but we still know relatively little about the antecedents, strategies, and processes that make it possible within companies. This paper aims at explaining how food manufacturers can prevent the degradation of generated surplus food into waste. Based on an extensive literature review and 4 exploratory case studies, research questions are formulated about (i) available avenues for managing surplus food, and (ii) internal drivers that make these avenues viable and efficient. In order to adapt, refine and corroborate the conceptual framework, the research conducts 10 descriptive case studies of Italian food manufacturers. Results from the cross-case analysis highlight the multiplicity of reuse and redistribution options, and their viability over the product shelf life. The analysis also shows that a structured surplus food control system and partnerships with food aid organizations are necessary to reduce food waste

Comparison of cross-matching method for detection of DEA 7 blood incompatibility

We compared 3 major cross-match (XM) tests to identify dog erythrocyte antigen (DEA) 7 blood incompatibilities in dogs as a result of anti\u2013DEA 7 antibodies: gel (GEL), standard tube (TUBE) agglutination, and immunochromatography strips (STRIP). Blood samples from 42 dogs were typed for DEA 7; 2 tested DEA 7\u2013positive (DEA 7+). The 40 DEA 7\u2013negative (DEA 7\u2013) plasma samples were cross-matched against the 2 DEA 7+ and 3 DEA 7\u2013 red blood cell (RBC) samples by GEL to identify samples with anti\u2013DEA 7 antibodies. Twenty DEA 7\u2013 plasma samples without and with anti\u2013DEA 7 antibodies were cross-matched with samples of the 2 DEA 7+ RBCs in a double-blind fashion using the TUBE and STRIP XM methods. GEL results were used as the reference method for comparison. To determine relationships between results, 2 7 2 tables were used. Cohen kappa coefficient (\u3ba) was calculated between results of GEL and the other 2 methods. With GEL, 21 of 40 XM tests were positive and 19 of 40 negative for anti\u2013DEA 7 antibodies. The same results were obtained by TUBE, whereas only 1 of 40 XM tests was positive by STRIP. There was a statistically significant relationship between results of GEL and TUBE (p < 0.000) with perfect agreement (\u3ba = 1.000), but not between GEL and STRIP results (p = 1.000) in which agreement was equivalent to chance (\u3ba = 0.0453). The GEL and TUBE XM tests, but not STRIP, are useful methods for identification of DEA 7 incompatibilities caused by anti\u2013DEA 7 antibodies

Modulation of cell growth and cisplatin sensitivity by membrane gamma-glutamyltransferase in melanoma cells.

The plasma membrane enzyme c-glutamyltransferase (GGT) is regarded as critical for the maintenance of intracellular levels of glutathione (GSH). GGT expression has been implicated in drug resistance through elevation of intracellular GSH. The dependence of intracellular GSH on GGT expression was not conclusively ascertained. The present study was designed to investigate the role of GGT and of intracellular GSH levels in modulating proliferation and sensitivity to cisplatin of melanoma cells. GGT transfection resulted in increased growth, both in vitro and in tumour xenografts. In addition, GGT-transfected cells exhibited reduced sensitivity to cisplatin associated with lower DNA platination. A decrease in intracellular GSH levels, rather than an increase, was observed in GGT-transfected cells; moreover, in cysteine-deficient conditions, the expression of GGT did not provide transfected cells with the ability of utilising extracellular GSH. In conclusion, these results indicate that GGTactivity confers a growth advantage unrelated with intracellular glutathione supply, and are consistent with the interpretation that cisplatin resistance is the consequence of modifications of cellular pharmacokinetics as a result of extracellular drug inactivation by thiol metabolites originated by GGT-mediated GSH cleavage

Octreotide Conjugates for Tumor Targeting and Imaging

Tumor targeting has emerged as an advantageous approach to improving the efficacy and safety of cytotoxic agents or radiolabeled ligands that do not preferentially accumulate in the tumor tissue. The somatostatin receptors (SSTRs) belong to the G-protein-coupled receptor superfamily and they are overexpressed in many neuroendocrine tumors (NETs). SSTRs can be efficiently targeted with octreotide, a cyclic octapeptide that is derived from native somatostatin. The conjugation of cargoes to octreotide represents an attractive approach for effective tumor targeting. In this study, we conjugated octreotide to cryptophycin, which is a highly cytotoxic depsipeptide, through the protease cleavable Val-Cit dipeptide linker using two different self-immolative moieties. The biological activity was investigated in vitro and the self-immolative part largely influenced the stability of the conjugates. Replacement of cryptophycin by the infrared cyanine dye Cy5.5 was exploited to elucidate the tumor targeting properties of the conjugates in vitro and in vivo. The compound efficiently and selectively internalized in cells overexpressing SSTR2 and accumulated in xenografts for a prolonged time. Our results on the in vivo properties indicate that octreotide may serve as an efficient delivery vehicle for tumor targeting.Peer reviewe

Inhibition of proteasome deubiquitinating activity as a novel cancer therapy

Ubiquitin-tagged substrates are degraded by the 26S proteasome, which is a multisubunit complex comprising a proteolytic 20S core particle capped by 19S regulatory particles. The approval of bortezomib for the treatment of multiple myeloma validated the 20S core particle as an anticancer drug target. Here we describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14), resulting in accumulation of polyubiquitin. b-AP15 induced tumor cell apoptosis that was insensitive to TP53 status and overexpression of the apoptosis inhibitor BCL2. We show that treatment with b-AP15 inhibited tumor progression in four different in vivo solid tumor models and inhibited organ infiltration in an acute myeloid leukemia model. Our results show that the deubiquitinating activity of the 19S regulatory particle is a new anticancer drug target.CancerfondenRadiumhemmets forskningsfonderVetenskapsrådetStrategiska forskningsstiftelsenVinnovaEuropean Union CHEMORES, Frame program 6 (LSHC-CT-2007-037665)Swedish Children Cancer SocietyAccepte